Canada Pension Plan Investment Board Boosts Stake in DexCom, Inc. (NASDAQ:DXCM)

Canada Pension Plan Investment Board lifted its stake in DexCom, Inc. (NASDAQ:DXCMFree Report) by 2.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 293,771 shares of the medical device company’s stock after buying an additional 6,200 shares during the quarter. Canada Pension Plan Investment Board owned approximately 0.08% of DexCom worth $27,409,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of DXCM. Atlas Capital Advisors LLC bought a new position in shares of DexCom during the 2nd quarter valued at about $33,000. NBC Securities Inc. bought a new position in DexCom during the third quarter valued at approximately $47,000. Thompson Siegel & Walmsley LLC purchased a new position in DexCom during the 3rd quarter valued at approximately $48,000. Valley National Advisers Inc. increased its stake in DexCom by 33.5% in the 2nd quarter. Valley National Advisers Inc. now owns 379 shares of the medical device company’s stock worth $49,000 after acquiring an additional 95 shares during the last quarter. Finally, FinTrust Capital Advisors LLC raised its holdings in shares of DexCom by 139.3% during the 3rd quarter. FinTrust Capital Advisors LLC now owns 536 shares of the medical device company’s stock worth $50,000 after acquiring an additional 312 shares in the last quarter. 93.88% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Performance

Shares of DexCom stock opened at $120.47 on Friday. The company has a quick ratio of 2.50, a current ratio of 2.80 and a debt-to-equity ratio of 1.07. The stock’s fifty day moving average is $123.34 and its two-hundred day moving average is $108.50. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $139.55. The company has a market capitalization of $46.55 billion, a PE ratio of 91.96, a price-to-earnings-growth ratio of 2.35 and a beta of 1.20.

DexCom (NASDAQ:DXCMGet Free Report) last issued its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.07. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 27.88%. The business’s revenue was up 26.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.34 earnings per share. As a group, analysts expect that DexCom, Inc. will post 1.73 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other news, CEO Kevin R. Sayer sold 37,325 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $123.63, for a total transaction of $4,614,489.75. Following the transaction, the chief executive officer now directly owns 362,841 shares of the company’s stock, valued at $44,858,032.83. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Steven R. Altman sold 1,000 shares of DexCom stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $101.26, for a total value of $101,260.00. Following the completion of the sale, the director now directly owns 59,700 shares in the company, valued at $6,045,222. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 37,325 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $123.63, for a total transaction of $4,614,489.75. Following the transaction, the chief executive officer now owns 362,841 shares in the company, valued at $44,858,032.83. The disclosure for this sale can be found here. Insiders sold a total of 58,098 shares of company stock valued at $7,091,785 in the last three months. Company insiders own 0.41% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of recent research reports. SVB Leerink assumed coverage on shares of DexCom in a report on Monday, October 16th. They issued an “outperform” rating and a $110.00 target price for the company. Piper Sandler boosted their target price on shares of DexCom from $135.00 to $150.00 and gave the stock an “overweight” rating in a report on Tuesday, December 19th. Raymond James increased their price target on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 23rd. JPMorgan Chase & Co. reduced their price objective on DexCom from $160.00 to $100.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 17th. Finally, Morgan Stanley raised their price objective on DexCom from $101.00 to $122.00 and gave the company an “equal weight” rating in a research note on Monday, December 4th. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $134.64.

Check Out Our Latest Stock Analysis on DexCom

DexCom Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Featured Articles

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMFree Report).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.